Skip to main content

25-09-2017 | Gastrointestinal cancer | News | Article

ESMO 2017 in brief

FLOT4-AIO results could guide operable gastric cancer treatment

medwireNews: Perioperative docetaxel, oxaliplatin, and 5-fluorouracil/leucovorin (FLOT) treatment should be a new standard of care for patients with operable adenocarcinoma of the stomach or gastroesophageal junction, say the FLOT4-AIO trial investigators.

Compared with the 360 patients given epirubicin, cisplatin, and infused 5-fluorouracil (ECF), prespecified sensitivity analysis indicated that the 356 patients randomly assigned to receive FLOT achieved significantly greater overall survival (OS), with a hazard ratio (HR) of 0.76. This finding was strengthened in multivariate analysis, which gave a HR of 0.74 for OS after taking into consideration age, tumor location, and other confounding factors.

And post-hoc analysis showed a progression-free survival (PFS) benefit with FLOT regardless of whether patients underwent surgery, and that the improvement in OS with FLOT occurred independently of tumor markers such as nodal status, and the presence of Barrett mucosa or Signet cell component disease.

These findings follow earlier FLOT4-AIO results for curative resection, OS, and PFS in favor of FLOT chemotherapy that were presented at the ASCO 2017 meeting in Chicago, Illinois, USA, Salah-Eddin Al Batran (University Cancer Center Frankfurt, Germany) told delegates at ESMO 2017 Congress in Madrid, Spain.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group